Subjective Measures, Objective Outcomes: Data Quality In Atopic Dermatitis Trials

By Maria Visser and Martina Micaletto

Atopic Dermatitis (AD) is a common skin condition, and recent advancements in AD therapies have led to a surge in clinical trial activity. Precise measurement of disease severity is crucial for assessing treatment effectiveness in these trials.

This blog explores essential tools like the Eczema Area and Severity Index (EASI) and Total Body Surface Area (BSA), highlighting their distinct roles and applications. EASI evaluates disease severity across various body regions, while BSA quantifies the extent of skin involvement. Differences in these measurement approaches can influence data interpretation. To improve reliability, standardization, rater training, and advanced data analytics are recommended. These strategies aim to enhance data quality and support the success of AD clinical trials.

For a more detailed discussion, read the full article below.